Targeting of TNF-α through recombinant antibody has found application in several inflammatory diseases such as neuroinflammatory and autoimmune diseases (e.g. rheumatoid arthritis, multiple sclerosis, and inflammatory bowel diseases) and cancer12,41–43, but a proportion of patients may encounter adverse events43,44. This evidence concerns the gene TNF and rheumatoid arthritis.